ALAMEDA, Calif.– BioTime, Inc. (NYSE MKT: BTX) today announced that Franklin M. Berger, CFA, 63, has been appointed to its Board of Directors.

“We are pleased to welcome a recognized biotechnology industry expert of Franklin’s caliber to BioTime’s Board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Franklin adds to our Board a great deal of experience as a director of biotechnology companies, as an advisor to biopharma, and as a recognized leader in the analysis and financing of biotechnology companies. His deep understanding of the scientific, technological, business, and financial aspects of the biotechnology sector, coupled with his extensive analytical, financial, and board experience, will be valuable additions to our Board during an exciting period of growth for BioTime.”

“BioTime’s development and acquisition of novel technologies in the stem cell space over the last few years has established it as a leader in regenerative medicine,” said Mr. Berger. “Regenerative medicine has the potential to be the next major step forward in biotechnology, and may lead to significant improvements in the health and quality of life of patients around the world. I am honored to join the BioTime Board of Directors as the company moves toward the expansion of its technology platform and its entry into clinical trials, and look forward to contributing to the development of these new technologies.”

Mr. Berger currently serves as a director of several biotechnology companies both public and private, and as a consultant to major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital firms. In addition to his board roles, he routinely advises companies regarding business development, strategic advisory/financings, partnering, and royalty acquisition. In October 2011, Mr. Berger accepted the position of Senior Advisor to PDL BioPharma, Inc., a premier biotech royalty company. He currently serves on the boards of three public biotechnology companies, Seattle Genetics, Thallion Pharmaceuticals, and Bellus Health, Inc. He also serves on the board of Five Prime Therapeutics, Inc., a private biotech company, and he has previously served on the boards of several other public and private biotechnology companies. Mr. Berger’s distinguished career in the investment industry included roles in investment management and over twelve years as a leading equity research analyst covering biotechnology companies, most recently as Managing Director,U.S. Equity Research, at J.P. Morgan Securities, Inc. from 1998 to 2003. During the course of his career, Mr. Berger was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities, including Roche’s Genentech initial public offering in 1999, the largest biotechnology financing to date. Mr. Berger received his BA and MA degrees from Johns Hopkins University in 1971 and 1972, respectively, and received his MBA degree from Harvard University in 1975.

Also, Arnold I. Burns, 83, retired from BioTime’s Board of Directors. Mr. Burns notified the BioTime Board that due to health concerns, he could no longer continue to productively serve as a director. “Arnie’s advice and counsel will be sorely missed by our Board,” said Mr. Kingsley. “We look forward to consulting with Arnie from time to time in the future, and wish him well as he focuses on other matters.”